Published in Cancer Weekly, July 29th, 2003
According to a study from the United States, "Heregulin (HRG) is an activator of the erbB2-, erbB3- and erB4-(erbB-2/3/4) signaling pathway.
"Transfection of full-length HRG cDNA into the estrogen (E2)-dependent cell line MCF-7 promoted an invasive E2-independent phenotype, as well as persistent activation of the erbB-2/3/4 receptors. Moreover, HRG expression in MCF-7 cells renders the cells sensitive to the topoisomerase 11 inhibitor doxorubicin (Doxo)," wrote E. Atlas and colleagues, Northwestern University, Evanston Northwestern Healthcare Research Institute.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.